Methods and compositions for improving or maintaining skin health in mammals

Through the ergothione composition, the skin problems caused by skin microorganisms are suppressed and beneficial microorganisms are promoted, and the skin problems caused by skin microorganism disorders are solved, which significantly improves skin health and elasticity, enhances skin moisture and reduces inflammation.

CN116350529BActive Publication Date: 2024-11-15NANJING NUTRABUILDING BIO TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211606160.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-12
Publication Date
2024-11-15
Estimated Expiration
2042-12-12

AI Technical Summary

Technical Problem

Skin microbial disorders lead to a series of skin problems, such as inflammation, dryness, lack of elasticity and luster. The prior art has failed to effectively inhibit the overgrowth of microorganisms that cause skin problems or promote the growth of beneficial microorganisms, affecting skin health.

Method used

Use ergothionine or a pharmaceutically acceptable composition of salts, acids, esters, analogs or derivatives thereof to inhibit the growth of microorganisms that cause skin problems and promote beneficial microorganisms for the preparation of individuals Care products, cosmetics or medications.

Benefits of technology

Significantly inhibit the growth of skin problem microorganisms, promote the growth of beneficial microorganisms, improve skin condition, increase skin elasticity and moisture, reduce inflammation and other skin problems, and maintain skin health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116350529B_ABST
    Figure CN116350529B_ABST
Patent Text Reader

Abstract

The present invention discloses a method and composition for improving or maintaining the skin health of a mammal and related applications thereof in preparing personal care products, cosmetics or medicines for improving or maintaining the skin health of a mammal. The method and composition of the present invention can inhibit the growth of microorganisms that cause skin problems, and / or promote the growth of microorganisms that are beneficial to the skin, and / or eliminate or alleviate skin problems.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of cosmetics and personal care products, and specifically relates to a method and composition for improving or maintaining the skin health of mammals, and related applications thereof in preparing personal care products, cosmetics or medicines for improving or maintaining the skin health of mammals. Background Art

[0002] The skin is home to a variety of microorganisms that depend on and restrict each other to form a mutually stable and harmonious biological barrier, which together maintains the balance of the skin's microecology and plays an important physiological role. Therefore, skin microorganisms are important members of the skin's microecological system and play an important role in maintaining skin health.

[0003] In general, bacteria and fungi are important components of the skin microbiome and together maintain the functioning of the skin. The majority of skin bacteria (>90%) are mainly Actinobacteria (52%), Firmicutes (24%), Proteobacteria (16%) and Bacteroidetes (6%), while the main genus of skin fungi is Malassezia.

[0004] However, skin microorganisms may increase, decrease or even disappear abnormally due to some uncontrollable factors, and the skin microbial state may be unbalanced, which may lead to a series of skin problems such as atopic dermatitis and acne. For example, the overgrowth of Malassezia, Propionibacterium acnes, Staphylococcus epidermidis, Cutibacterium spp., Corynebacterium spp., etc. can cause inflammation. On the other hand, there are a large number of Streptococcus species in young individuals or individuals with more elastic skin; the reduction of Streptococci, such as Streptococcus pneumoniae, Streptococcus infantis and Streptococcus thermophilus, can lead to skin problems such as lack of skin elasticity and luster, fine lines, sagging and dryness. Therefore, inhibiting the growth of these microorganisms that cause skin problems and / or promoting the growth of beneficial skin microorganisms such as Streptococcus can significantly improve skin conditions and maintain skin health.

[0005] In summary, skin microbial imbalance can lead to skin damage, followed by inflammation and dry skin, lack of elasticity and luster, fine lines, sagging, aging and other problems. Ergothioneine (EGT) is a safe natural compound with excellent anti-inflammatory and antioxidant properties. In addition, it has been reported that EGT has a good regulatory effect on intestinal microorganisms (Matsuda, Ozawa et al. 2020), but there has been no research on the interaction between EGT and skin microbiota, especially by inhibiting the excessive growth of microorganisms that cause skin problems, thereby eliminating or inhibiting skin inflammation; or promoting the growth of microorganisms that are beneficial to the skin, thereby protecting skin health. Summary of the invention

[0006] To achieve the above object, in one aspect, the present invention provides a method for improving or maintaining mammal skin health, the method comprising applying a composition to a mammal, the composition comprising an effective amount of ergothioneine or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof. In some embodiments, the composition further comprises a pharmaceutically acceptable carrier.

[0007] In some embodiments, improving or maintaining mammalian skin health comprises inhibiting the growth of microorganisms that cause skin problems, and / or promoting the growth of microorganisms that are beneficial to the skin, and / or eliminating or alleviating skin problems.

[0008] In some embodiments, the microorganisms causing skin problems are selected from one or more of the following: Staphylococcus epidermidis, Corynebacterium, Keratinobacterium, Propionibacterium acnes, Malassezia; the microorganisms beneficial to the skin are Streptococcus; the skin problems are selected from one or more of the following: skin inelasticity, dry skin, desquamation, dull skin, fine lines, sagging, inflammation, peeling, acne, atopic dermatitis, eczema, chloasma, erythema, papules, itching. In some embodiments, the microorganisms beneficial to the skin can be Streptococcus, such as Streptococcus pneumoniae, Streptococcus infantis, Streptococcus thermophilus, etc.; or other similar microorganisms. In some embodiments, inflammation may be folliculitis, seborrheic dermatitis, etc.

[0009] In some embodiments, the composition is used in the preparation of a personal care product, a cosmetic, or a medicament.

[0010] In some embodiments, the composition is prepared in the form of a lotion, cream, ointment, serum, paste, gel, solution, dispersion, spray, suspension, emulsion, foam, patch, powder, film, spirit, tincture, and liniment.

[0011] In some embodiments, ergothioneine or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof is formulated for administration in an amount of 1-1500 mg per day, preferably 1-1000 mg, 2-500 mg, 3-100 mg, 4-50 mg or 5-30 mg per day.

[0012] In some embodiments, the composition is administered topically, transdermally, or subcutaneously.

[0013] On the other hand, the present invention provides a composition comprising ergothioneine or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof, for improving or maintaining mammalian skin health. In some embodiments, the composition further comprises a pharmaceutically acceptable carrier.

[0014] In some embodiments, the composition inhibits the growth of microorganisms that cause skin problems, and / or promotes the growth of microorganisms that are beneficial to the skin, and / or eliminates or alleviates skin problems.

[0015] In some embodiments, the microorganisms causing skin problems are selected from one or more of the following: Staphylococcus epidermidis, Corynebacterium, Keratinobacterium, Propionibacterium acnes, Malassezia; the microorganisms beneficial to the skin are Streptococcus; the skin problems are selected from one or more of the following: skin inelasticity, dry skin, desquamation, dull skin, fine lines, sagging, inflammation, peeling, acne, atopic dermatitis, eczema, chloasma, erythema, papules, itching. In some embodiments, the microorganisms beneficial to the skin can be Streptococcus, such as Streptococcus pneumoniae, Streptococcus infantis, Streptococcus thermophilus, etc.; or other similar microorganisms. In some embodiments, inflammation may be folliculitis, seborrheic dermatitis, etc.

[0016] In some embodiments, the composition is used in the preparation of personal care products, cosmetics or medicines. In some embodiments, the composition is prepared in the form of lotions, creams, ointments, essences, pastes, gels, solutions, dispersions, sprays, suspensions, emulsions, foams, patches, powders, films, spirits, tinctures and liniments.

[0017] In some embodiments, ergothioneine or its pharmaceutically acceptable salt, acid, ester, analog or derivative is formulated to be used in an amount of 1-1500 mg per day, preferably 1-1000 mg, 2-500 mg, 3-100 mg, 4-50 mg or 5-30 mg per day. In some embodiments, the composition is administered by a route such as topical, transdermal or subcutaneous administration.

[0018] On the other hand, the present invention provides a composition for preparing a personal care product, cosmetic or medicine for improving or maintaining the skin health of a mammal, the composition comprising an effective amount of ergothioneine or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof. In some embodiments, the composition further comprises a pharmaceutically acceptable carrier.

[0019] In some embodiments, the composition inhibits the growth of microorganisms that cause skin problems, and / or promotes the growth of microorganisms that are beneficial to the skin, and / or eliminates or alleviates skin problems. In some embodiments, the microorganisms that cause skin problems are selected from one or more of the following: Staphylococcus epidermidis, Corynebacterium, Keratinobacterium, Propionibacterium acnes, Malassezia; the microorganisms that are beneficial to the skin are Streptococci; the skin problems are selected from one or more of the following: skin inelasticity, dry skin, desquamation, dull skin, fine lines, sagging, inflammation, peeling, acne, atopic dermatitis, eczema, chloasma, erythema, papules, itching. In some embodiments, the microorganisms that are beneficial to the skin can be streptococci, such as Streptococcus pneumoniae, Streptococcus infantis, Streptococcus thermophilus, etc.; or other similar microorganisms. In some embodiments, inflammation may be folliculitis, seborrheic dermatitis, etc.

[0020] In some embodiments, the composition is administered to a mammal in an amount of 1-1500 mg per day, preferably 1-1000 mg, 2-500 mg, 3-100 mg, 4-50 mg or 5-30 mg ergothioneine or its pharmaceutically acceptable salt, acid, ester, analog or derivative per day. In some embodiments, the composition is administered by a route such as topical, transdermal or subcutaneous administration. In some embodiments, the composition is prepared in the form of a lotion, cream, ointment, essence, paste, gel, solution, dispersion, spray, suspension, emulsion, foam, patch, powder, film, spirit, tincture and liniment.

[0021] This Summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 This is a comparison chart of Staphylococcus epidermidis counts after treatment with 1 μM α-GO and various concentrations of EGT.

[0023] Figure 2 This is a comparison chart of the coryneform bacteria counts after treatment with 1 μM α-GO and various concentrations of EGT.

[0024] Figure 3This is a comparison chart of the counts of Keratinobacterium after treatment with 1μM α-GO and various concentrations of EGT.

[0025] Figure 4 This is a comparison chart of Propionibacterium acnes counts after treatment with 1μM α-GO and various concentrations of EGT.

[0026] Figure 5 This is a comparison chart of the Malassezia counts after treatment with 1μM α-GO and various concentrations of EGT.

[0027] Figure 6 This is a comparison chart of the relative abundance (RA) of Streptococcus in the skin of the subjects after applying pure base cream, 5% EGT base cream and 10% EGT base cream.

[0028] Figure 7 This is a comparison chart of the subjects' skin elasticity, moisture and desquamation after applying pure base cream, 5% EGT base cream and 10% EGT base cream. DETAILED DESCRIPTION

[0029] Now will refer to preferred embodiments of the present invention in detail, further illustrate its embodiment.Although the present invention will be described in conjunction with preferred embodiments, it should be understood that they are not intended to limit the present invention to these embodiments.On the contrary, the present invention is intended to cover substitutions, modifications and equivalents, which may be included within the spirit and scope of the present invention as defined in the claims.

[0030] As used herein, the term "or" is intended to include "and" and "or." In other words, the term "or" may also be replaced with "and / or."

[0031] As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0032] As used herein, the term "comprises" or "includes" or variations thereof refer to the following instances where the term is used in its non-limiting sense, meaning that items following the term are included, but items not specifically mentioned are not excluded. It also includes the more restrictive verbs 'consisting essentially of' and 'consisting of'.

[0033] As used herein, the terms "mammal" or "subject" are used interchangeably to refer to any animal to which the methods and compositions of the present disclosure can be applied or administered. The animal may be suffering from an illness or other disease, but the animal does not need to be sick to benefit from the methods and compositions of the present disclosure. Therefore, any animal can utilize the disclosed compositions or be a recipient of the disclosed methods. Although the animal subject is preferably a human, the methods and compositions of the present invention are also applicable to veterinary medicine, for example, for treating domesticated species such as canines, felines, murines, and various other pets; farm animals, such as cattle, horses, sheep, goats, pigs, etc.; and wild animals, such as non-human primates in the wild or in zoos, etc.

[0034] As used herein, the term "administering" refers to the process of delivering the disclosed composition or active ingredient to a subject. The composition of the present invention is preferably administered topically, transdermally or subcutaneously, but may also be administered by other conventional routes to exert the desired effect.

[0035] As used herein, the term "effective amount" refers to the amount required to achieve the effects taught herein. The effective amount herein includes, but is not limited to, the amount necessary to improve or maintain the health of mammalian skin, and / or inhibit the growth of microorganisms that cause skin problems, and / or promote the growth of microorganisms that are beneficial to the skin, and / or eliminate or alleviate skin problems. According to the present disclosure, a suitable single dose size is a dose that can achieve the above effects when applied once or multiple times within a suitable time period.

[0036] As used herein, the term "pharmaceutically acceptable" means pharmaceutically, physiologically, cosmetically and / or cosmetically acceptable, and refers to those compositions or agents, materials or combinations of compositions and / or dosage forms thereof that are within the scope of sound medical judgment, suitable for contact with human and animal tissues, compatible with other ingredients of the composition, without excessive toxicity, irritation, allergic response or other problems or complications, and commensurate with a reasonable benefit / risk ratio.

[0037] As used herein, the term "carrier" may include liquid or solid fillers, diluents, excipients, solvents, encapsulating materials, buffers, stabilizers, preservatives, oils, surfactants, gelling agents, antioxidants, chelating agents, viscosity increasing agents, ultraviolet absorbers, pH regulators, pigments, fragrances, etc. The carrier used in the present invention is preferably a carrier suitable for personal care products, cosmetics, beauty products or medicines.

[0038] Method of the present invention comprises using at least 1mg every day, typically 1-1500mg, preferably 1-1000mg, 2-500mg, 3-100mg, 4-50mg or 5-30mg ergothioneine or its pharmaceutically acceptable salt, acid, ester, analog or derivative, this depends on specific preparation and form.Amount to be used can also change according to factors such as the sensitivity, age, sex and body weight, idiosyncratic reactions of experimenter.One or more dosages can be used once or repeatedly every day or with suitable frequency in any time period.For example, effective dose can be used every day, continue one day, several days, many days or use every day indefinitely.

[0039] The following examples are illustrative of selected embodiments of the invention and are not meant to limit the scope of the invention.

[0040] Example 1

[0041] Primary adult human dermal fibroblasts were embedded in a fibrin matrix to create dermal equivalents. The dermal equivalents were cultured to allow the fibroblasts to reconstruct the matrix. Primary neonatal human keratinocytes were applied to the surface of the dermal equivalents and cultured under liquid for 48 hours. Culture was performed at an air-liquid interface (ALI) until a stratified epidermis was formed.

[0042] Staphylococcus epidermidis, Corynebacterium, Keratinibacterium, Propionibacterium acnes and Malassezia were cultured in appropriate culture medium and incubation conditions (37±2℃, 5±1% (v / v) CO2, ≥95% RH). Inoculation buffer (GS25) was used to prepare the above bacteria containing about 1.1×10 6 cfu·mL -1 Inoculum of microbial flora. 10 μL of the mixture was used for colonization of the skin (epidermis), with each unit equivalent to approximately 10 of each bacterium. 4 cfu cm -2 Afterwards, the stratified epidermis was incubated at 37±2°C, 5±1% (v / v) CO2, ≥95% RH for 3±1 hours.

[0043] α-Glucan Oligosaccharide (α-GO) is a well-known prebiotic that can protect skin health by maintaining the balance of the microbiome and strengthening the skin's microbial barrier, so it was used as a control in the experiment. The control (α-GO, 1μM) and various concentrations of EGT (0μM, 0.1μM, 1μM, 10μM, 100μM, 1000μM) were applied to the above-mentioned stratified epidermis, and then incubated at 37±2℃, 5±1% (v / v) CO2, ≥95% RH for 24±2 hours. Then, the above five microorganisms were counted separately to evaluate the efficacy of α-GO and EGT in inhibiting microbial growth: 8mm biopsy sections were taken from the stratified epidermis, and the number of viable bacteria (cfu·cm -2 ). The choice of solid culture medium is based on the characteristics of the microorganism itself.

[0044] Figure 1-5 The following are the comparison charts of the counts of Staphylococcus epidermidis, Corynebacterium, Keratinobacterium, Propionibacterium acnes and Malassezia after treatment with 1 μM α-GO and various concentrations of EGT. Figure 1-5 As shown in the figure, the colonization of Staphylococcus epidermidis, Corynebacterium, Keratinobacterium, Propionibacterium acnes and Malassezia in the stratified epidermis treated with EGT was significantly inhibited. The inhibitory effect becomes more significant with the increase of EGT concentration, so that the number of microorganisms is maintained in a healthy state. In addition, at the same concentration (1μM), EGT has a significantly better inhibitory effect on the above five microorganisms than α-GO.

[0045] Example 2

[0046] 30 healthy women aged 20-59 were randomly divided into three groups. The first group (0% EGT, n = 10) was applied with pure base cream as a control group, the second group (5% EGT, n = 10) was applied with base cream mixed with 5% ergothioneine, and the third group (10% EGT, n = 10) was applied with base cream mixed with 10% ergothioneine. Apply once a day for 4 weeks. Skin microorganisms were collected on the 0th day and the 28th day, and the elasticity, moisture and desquamation of the subjects' skin were measured on the 28th day. The participants' faces were cleaned with sterile water and then smeared on solid tryptic soy agar (TSA) medium. Single colonies were collected and cultured in liquid tryptic soy broth (TSB) medium at 37°C for 72 hours.

[0047] Each sample was centrifuged and the precipitate was collected, and the microbial DNA in the precipitate was extracted using a specific kit. DNA purity and quantity were estimated using a spectrophotometer. The bacterial 16S rRNA gene was amplified using the following primers: forward, 5'-AGAGTTTGATCMTGGCTCAG-3'; reverse, 5'-TACGGYTACCTTGTTACGACTT-3'. PCR was performed in a 25 μL reactor containing 2 μL genomic DNA (10 ng / μL), 0.5 μL of each primer (10 μM), 12.5 μL 2× KAPA HiFi Hot Start Ready Mix, and 9.5 μL distilled water. The following PCR conditions were used: initial denaturation at 95°C for 3 min; denaturation at 95°C for 1 min, annealing at 55°C for 1 min, and extension at 75°C for 90 s for 30 cycles; and final extension at 72°C for 8 min. The PCR products were sequenced on an ABI-3730XL DNA sequencer and NCBI Microbial Nucleotide BLAST and Mega-BLAST were used to identify the 16S rRNA fragments.

[0048] Figure 6 The figure is a comparison of the relative abundance (RA) of Streptococcus in the skin of the subjects after applying pure base cream, 5% EGT base cream and 10% EGT base cream. Figure 6 As shown, the Streptococcus in the EGT base cream group was more abundant than that in the pure base cream group, that is, EGT can promote the growth of microorganisms that are beneficial to the skin, such as Streptococcus; and the effect of the 10% EGT group was more obvious.

[0049] Figure 7 This is a comparison chart of the skin elasticity, moisture and desquamation of the subjects after applying pure base cream, 5% EGT base cream and 10% EGT base cream. Figure 7 As shown, EGT can significantly increase the skin elasticity and moisture of the subjects and avoid the problem of skin desquamation. The effect of the 10% EGT group was more obvious, increasing skin elasticity by about 20% and skin moisture by about 45% and reducing desquamation by about 30% compared with the 0% EGT group.

[0050] The inventors have found that EGT has a positive effect on the regulation of microbial flora, and can significantly inhibit the (excessive) growth of Staphylococcus epidermidis, Corynebacterium, Keratinobacterium, Propionibacterium acnes, Malassezia and other microorganisms that are prone to skin problems; can promote the growth of streptococci, such as Streptococcus pneumoniae, Streptococcus infantis, Streptococcus thermophilus and other microorganisms that are beneficial to the skin; can also eliminate or alleviate skin problems, such as skin inelasticity, dry skin, desquamation, dull skin, fine lines, sagging, inflammation, peeling, acne, atopic dermatitis, eczema, chloasma, erythema, papules, itching, folliculitis, seborrheic dermatitis, etc., for example, can increase skin elasticity and moisture and avoid skin desquamation. In short, EGT can repair skin damage, regulate skin microbial homeostasis, maintain and improve skin health, and improve skin condition and physiological function.

[0051] Although specific embodiments and examples of the present invention have been described herein, it will be appreciated by those skilled in the art that any modifications and variations may be made without departing from the principles of the present invention. The above embodiments and descriptions do not limit the scope of the present invention. Any combination of embodiments of the present invention, as well as any obvious extensions or the like, are within the scope of the present invention. In addition, the present invention encompasses any arrangement intended to achieve the same purpose, as well as all such variations and modifications within the scope of the appended claims.

Claims

1. A method for preparing a composition for improving or maintaining the health of mammalian skin comprising: The composition comprises an effective amount of ergothioneine, and the improvement or maintenance of mammalian skin health is to inhibit the growth of microorganisms that cause skin problems and / or promote the growth of microorganisms that are beneficial to the skin, wherein the microorganisms that cause skin problems are selected from one or more of the following: Staphylococcus epidermidis, Corynebacterium, Keratinobacterium, Propionibacterium acnes, and Malassezia; and the microorganisms that are beneficial to the skin are Streptococci.

2. The use according to claim 1, characterized in that The composition is used for preparing personal care products, cosmetics or medicines.

3. The use according to claim 1, characterized in that The composition is prepared in the form of lotion, ointment, paste, spray, suspension, emulsion, foam, patch, powder, film, spirit, tincture and liniment.

4. The use according to claim 1, characterized in that The composition is prepared in the form of cream, gel, solution or dispersion.

5. The use according to claim 1, characterized in that The ergothioneine is formulated for administration in an amount of 1-1500 mg per day.

6. The use according to claim 1, characterized in that: The composition is administered topically, transdermally or subcutaneously.